Type 2 Diabetes Mellitus
Conditions
Brief summary
Metformin is the 1st line treatment in all subjects with type 2 diabetes without a contraindication to its use. The compliance with the use of metformin is not optimal mainly owing to relatively frequent gastrointestinal side effects. However, hard data about the real compliance are currently not available. In this trial we aim at assessing the compliance with metformin intake using a combination of serum metformin measurement and a specific questionnaire. We will further evaluate the impact of different pharmacological forms of metformin (standard vs. XR - extended release) on its compliance and try to identify common characteristics associated with reduced compliance.
Interventions
DIAGNOSTIC_TESTMeasurement of plasma metformin levels
Subjects on chronic metformin therapy will have their plasma metformin levels measured during a regular check-up with glycated hemoglobin assessment.
Sponsors
Institute for Clinical and Experimental Medicine
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Type 2 diabetes mellitus on metformin therapy for at least 3 months
Exclusion criteria
\-
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Plasma metformin levels | At the time of measurement |
Countries
Czechia
Contacts
Primary ContactMartin Haluzik, Prof. DSc.
Outcome results
None listed